GlassScriptPhysician profile
Yvonne Bohn
NPI 1417058587
$6,987.83
in general payments reported to CMS, 2019-2025
45 companies · $1,312 in 2025
The $1,312 reported for 2025 was more than what 92% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,234 · 2020: $337 · 2021: $1,106 · 2022: $1,164 · 2023: $1,031 · 2024: $804 · 2025: $1,312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,147.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,263.11 | 2019-2025 | Lo Loestrin Fe, Orilissa |
| Mayne Pharma Commercial LLC | $627.73 | 2022-2025 | |
| Evofem Biosciences, INC. | $569.64 | 2020-2025 | Phexxi, Solosec, Phexx |
| Amgen INC. | $373.38 | 2019-2025 | Evenity, Prolia |
| Agile Therapeutics, INC. | $342.82 | 2021-2024 | Twirla |
| Exeltis, USA INC. | $327.08 | 2019-2025 | Slynd |
| Bayer Healthcare Pharmaceuticals INC. | $288.02 | 2019-2025 | |
| Hologic Sales and Service, LLC | $248.70 | 2019-2025 | Aptima, Thinprep 2000 Processor, Acessa Provu System |
| Novo Nordisk INC | $244.25 | 2023-2024 | Wegovy |
| Merck Sharp & Dohme LLC | $223.72 | 2019-2024 | Gardasil 9, Gardasil |
| Pfizer INC. | $201.85 | 2019-2025 | |
| Allergan, INC. | $195.02 | 2019-2020 | |
| Lupin INC. | $190.01 | 2019-2020 | |
| Therapeuticsmd, INC. | $174.01 | 2020-2022 | |
| Coopersurgical, INC. | $173.78 | 2019-2025 | Paragard T 380a, Paragard T 380a |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $163.68 | 2022-2025 | Perclot, Floseal |
| Aspira Women'S Health INC | $147.89 | 2021-2024 | Ova1 |
| Daiichi Sankyo INC. | $124.39 | 2021-2022 | |
| Astellas Pharma US INC | $112.36 | 2024-2025 | Veozah |
| Recordati_rare_diseases_inc. | $103.57 | 2025 | Isturisa |
| Exact Sciences Corporation | $100.39 | 2023-2025 | Cologuard Collection Kit |
| Sage Therapeutics, LLC | $98.34 | 2025 | Zurzuvae |
| Amag Pharmaceuticals, INC. | $80.75 | 2019 | |
| Myovant Sciences INC. | $66.54 | 2021-2022 | |
| Nevro Corp. | $59.41 | 2019 | |
| Becton, Dickinson and Company | $56.24 | 2022-2024 | Bd Onclarity, Bd Max System, Bd Max Instrument |
| Minerva Surgical, INC | $53.25 | 2023 | |
| Vertical Pharmaceuticals, LLC | $39.34 | 2019 | |
| Lilly USA, LLC | $37.28 | 2025 | Zepbound |
| Sanofi Pasteur INC. | $27.26 | 2024 | |
| Organon LLC | $25.97 | 2021-2022 | |
| Pacira Pharmaceuticals Incorporated | $24.32 | 2024 | Exparel |
| Duchesnay USA Incorporated | $22.56 | 2019 | |
| Supernus Pharmaceuticals, INC. | $20.63 | 2025 | Qelbree |
| Abbott Laboratories | $19.85 | 2023 | Proclaim |
| Cepheid | $19.78 | 2025 | Genexpert |
| Scynexis, INC. | $19.24 | 2022 | |
| Seqirus USA INC | $18.43 | 2022 | |
| Ascend Therapeutics US, LLC | $17.84 | 2023 | |
| Neuronetics, INC. | $17.64 | 2023 | Neurostar Tms Therapy System |
| Sumitomo Pharma America, INC. | $17.11 | 2025 | Myfembree |
| Millicent US INC | $16.99 | 2025 | Intrarosa, Femlyv |
| Avion Pharmaceuticals | $14.55 | 2021 | |
| Convatec INC. | $14.37 | 2019 | |
| Channel Medsystems, INC. | $4.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yvonne Bohn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.